Phase I Clinical Study of Tolerability, Safety and Pharmacokinetics of QHRD106 Injection in Chinese Healthy Subjects With Single and Multiple Doses
Latest Information Update: 29 Jul 2024
At a glance
- Drugs QHRD 106 (Primary) ; Kallikrein 1 modulators
- Indications Stroke
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Changzhou Qianhong Bio-pharma
Most Recent Events
- 02 May 2024 New trial record